[Update on postcoital hormonal contraception. Part 1]

Ginecologia clinica · 1988 · vol. 9(1) , pp. 64–5 · PMID:12315912 · W2294966681
Review OA: closed CC0
View on OpenAlex View on PubMed
⚙ AI-generated summary by qwen3.7-flash, 2026-10-10 ⓘ

This article reviews recent protocols for postcoital hormonal contraception, comparing the efficacy and side-effect profiles of low-dose estrogen-progestin combinations, progesterone alone, quingestanol acetate, and danazol.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

In recent years new protocols of post-coital hormonal contraception have been devised that cause fewer side-effects. 0.2 mg ethinyl-estradiol with 2 mg norgestrel twice within 72 hours after intercourse were among the first combinations that would utilize low doses of hormones. Other authors use even smaller doses; preparations for intramuscular injection are available if the woman vomits the tablets. Progesterone has been used alone within 12 hours following intercourse with a success rate close to estrogen-progestin combinations. Quingestanol acetate is used for 5 days, 0.9-1.5 mg/day. With danazol fewer side-effects are seen; 400 mg are taken twice within 72 hours with a good rate of success.

My notes (saved in your browser only)

MeSH descriptors

Contraceptives, Postcoital Ethinyl Estradiol Norgestrel Progesterone Biology Contraception Contraceptive Agents Contraceptive Agents, Female Contraceptives, Oral, Hormonal Endocrine System Family Planning Services Hormones Physiology Progestins

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-05-10T11:29:38.281912+00:00
pubmed
last seen: 2026-10-08T21:00:45.472718+00:00
License: CC0 · commercial use OK